Galera Therapeutics, a clinical stage biotech
developing products to reduce toxicity in radiotherapy patients, filed
on Friday with the SEC to raise up to $86 million in an initial public
offering.
The Malvern, PA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol GRTX. BofA Merrill Lynch, Citi, Credit Suisse and BTIG are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.